Mounjaro Maintenance: Staying On, Stepping Down and Stopping

Mounjaro (tirzepatide) maintenance means keeping weight off once the main weight-loss phase has slowed or you have reached a healthier weight. The evidence shows that weight is most reliably maintained by continuing treatment: in the SURMOUNT-4 trial, people who stopped after 36 weeks regained a substantial share of the weight they had lost within a year. Options include staying on your current dose, stepping down to a lower dose, or stopping with a structured plan. The UK licence lists 5mg, 10mg and 15mg as maintenance doses and does not set a maximum treatment duration, but there is no standard step-down schedule, so decisions should be made with your prescriber.

This guide covers what the trials show, how each option works in practice, what to expect if you stop, and how to plan for the long term. For an overview of the medicine, see our complete guide to Mounjaro in the UK or the Mounjaro hub.

Why maintenance matters

Obesity is increasingly recognised as a long-term, relapsing condition. When people lose weight by any method, the body responds with changes that push weight back up, including increased hunger hormones, reduced fullness signals and a fall in energy expenditure that is sometimes greater than expected for the new body size. These changes can persist for years.

Tirzepatide counteracts some of these effects by reducing appetite and increasing fullness. When it is stopped, those effects fade, but the body's drive to regain often remains. This is why regain after stopping is common, and why maintenance needs to be planned rather than left to chance. Our guide to obesity as a chronic disease explains the biology further.

What the evidence shows

SURMOUNT-4: continuing vs stopping

SURMOUNT-4, published in JAMA in 2024, is the key trial on what happens when tirzepatide stops.

People who switched to placebo regained a substantial share of their lost weight, and improvements in blood pressure, cholesterol and blood sugar partly reversed. On average, however, they remained below their starting weight at 88 weeks. The STEP 4 trial of semaglutide (Wegovy) found a very similar pattern, suggesting this is a feature of how these medicines work rather than of one product.

SURMOUNT-1: three years on treatment

Three-year results from SURMOUNT-1 participants with prediabetes, published in the New England Journal of Medicine in 2025, showed that weight loss was largely maintained over about 176 weeks of continued treatment, at around 12% to 20% depending on dose, compared with about 1% on placebo. The risk of developing type 2 diabetes was reduced by about 94%. When treatment stopped at the end of the trial, some regain followed.

SURMOUNT-MAINTAIN: stepping down

SURMOUNT-MAINTAIN was presented at the European Congress on Obesity in May 2026. Participants first took tirzepatide at their maximum tolerated dose for 60 weeks. They were then randomly assigned to continue that dose, step down to 5mg, or switch to placebo for a further 52 weeks.

The headline findings reported were:

• continuing the maximum tolerated dose was the most effective at maintaining weight loss and cardiometabolic improvements
• stepping down to 5mg retained most of the weight loss, with an average regain reported at around 5.6kg by week 112
• switching to placebo led to more regain than either tirzepatide group

These results suggest that a lower dose may be a reasonable option for some people who want to reduce their dose, for reasons such as side effects or cost, while recognising that it may not hold weight as well as continuing at the higher dose. At the time of writing, full peer-reviewed details should be checked as they become available, and the SmPC does not set out a step-down regimen.

ATTAIN-MAINTAIN: switching to a tablet

Also presented in May 2026, the ATTAIN-MAINTAIN trial studied people who had lost weight on injectable semaglutide or tirzepatide and then switched to once-daily orforglipron (Foundayo) tablets. Reported average regain over 52 weeks was small after switching from semaglutide (around 0.9kg) and larger after switching from tirzepatide (around 5kg). Foundayo was authorised by the MHRA for weight management in August 2026. See Switching from an injection to a GLP-1 tablet.

Your maintenance options

Option 1: stay on your current dose

This is the approach with the strongest support from trial evidence. If your weight is stable, side effects are manageable and you are happy to continue, your prescriber may simply keep you on the same dose with regular reviews.

Points to consider:

• Benefits: the strongest evidence for maintaining weight and health improvements.
• Drawbacks: ongoing side effects for some, the commitment of weekly injections and, for private treatment, continuing cost.

Option 2: step down to a lower dose

If you are on 10mg or 15mg and your weight has stabilised, your prescriber may consider a lower dose, such as 5mg, while monitoring your weight closely.

Points to consider:

• Benefits: possibly fewer side effects and lower private cost; SURMOUNT-MAINTAIN suggests much of the weight loss may be retained.
• Drawbacks: some regain is likely for many people; there is no licensed step-down protocol, so it relies on clinical judgement.

Option 3: stop with a structured plan

Some people stop because they have reached their goal, have side effects, are planning a pregnancy, are having surgery or can no longer afford private treatment.

Points to consider:

• Benefits: no injections, side effects or medicine costs.
• Drawbacks: the highest risk of regain based on current evidence.

Approaches not supported by evidence

You may see suggestions online for extending the gap between injections (for example, every ten days or every fortnight), splitting doses or "microdosing". These are not part of the licensed dosing in the UK SmPC and have not been tested in robust trials. Changing the interval can also cause confusion over missed doses. Talk to your prescriber rather than experimenting.

What happens in your body when you stop

Tirzepatide has a half-life of about five days, so most of the medicine has left your body within a few weeks of the last dose. People commonly report:

• appetite and portion sizes gradually increasing
• more frequent thoughts about food
• digestive side effects such as nausea easing
• weight beginning to rise over weeks to months, often faster at first

There is no withdrawal syndrome in the usual sense, and the product information does not require a taper. Some prescribers prefer a gradual reduction so that appetite returns more slowly, but there is limited evidence comparing tapering with stopping outright.

If you have type 2 diabetes, stopping tirzepatide is likely to raise your blood sugar, and your diabetes treatment may need adjusting. This should always be planned with your clinician. See weight regain after stopping GLP-1 medication.

Signs you may be moving into maintenance

There is no single point at which maintenance begins, but common signs include:

• your weight has been broadly stable for several weeks on a consistent dose
• you have reached a weight you and your prescriber agreed was a reasonable goal
• further dose increases are not expected to add much, or are limited by side effects
• your health markers, such as blood pressure or blood sugar, have improved and stabilised

Recognising this stage helps shift the focus from losing weight to protecting the progress you have made, including your health improvements, muscle strength and habits.

The psychological side of maintenance

Maintenance can feel less rewarding than the weight-loss phase, because the scales stop moving. Some people also worry about regain or feel uncertain about how long to continue treatment. Points that people often find helpful:

• Reframe success. A stable weight is a successful outcome, not a stall.
• Watch for all-or-nothing thinking. A heavier week does not undo months of progress.
• Notice changes in eating behaviour. If you feel out of control around food, especially after stopping, speak to your prescriber or GP. Support for disordered eating is available.
• Keep the conversation open. Regular reviews with your prescriber help you adjust before small changes become large ones.

See GLP-1 medication and mental health.

Building a maintenance plan

Whatever option you choose, the following elements are commonly recommended.

1. Agree a plan with your prescriber

Discuss which option suits you, what you will monitor and what you will do if weight rises. A clear plan might include a weight threshold that triggers a review.

2. Prioritise protein and food quality

Eating enough protein helps preserve muscle, which supports metabolism and physical function. As appetite returns after stopping, structured meals built around protein, vegetables, fibre and wholegrains can help with fullness. See protein intake on weight loss injections and what to eat on GLP-1 medication.

3. Keep up strength and activity

Resistance exercise helps maintain muscle, and regular physical activity is one of the strongest predictors of weight maintenance in long-term studies of weight loss. See preserving muscle mass on GLP-1 treatment and exercise on GLP-1 medication.

4. Look after sleep and stress

Poor sleep and chronic stress can increase appetite and cravings. Addressing them is a practical part of maintenance.

5. Monitor regularly

Weighing yourself regularly, for example weekly, and tracking waist measurement helps spot regain early. See measuring progress beyond the scales.

6. Know when to act

Small fluctuations are normal. A sustained rise over several weeks is a reason to contact your prescriber, who may suggest adjusting your approach or restarting treatment.

Restarting Mounjaro

If you stop and later restart, your prescriber will decide on the dose. Because tolerance to digestive side effects falls after a break, many prescribers restart at a lower dose and step up again rather than returning straight to your previous dose. The SmPC does not define a re-titration schedule for longer breaks. See Mounjaro doses explained and Missed a Mounjaro dose?.

Maintenance for particular groups

Older adults

Older people lose muscle more readily with age, and weight loss can add to this. Maintaining muscle strength, balance and bone health is especially important. Your prescriber may place more emphasis on protein intake, resistance exercise and monitoring for unintended loss of muscle or frailty. See GLP-1 medication for people over 65.

People with type 2 diabetes

For people with type 2 diabetes, tirzepatide also helps control blood sugar, so decisions about stepping down or stopping affect diabetes management as well as weight. Your diabetes team will consider whether other medicines need to be added or adjusted. Stopping without a plan can lead to a rise in blood sugar as well as weight.

People who reached a lower BMI than expected

Some people lose a large amount of weight and approach the lower end of the healthy BMI range. Continuing at a high dose in this situation may not be appropriate, and your prescriber may suggest stepping down. Unintended or excessive weight loss should always be discussed.

Special situations

Planning a pregnancy

Mounjaro should not be used in pregnancy. The SmPC advises stopping at least one month before a planned pregnancy, because of the time the medicine takes to leave the body. See GLP-1 medication, pregnancy and fertility.

Surgery and procedures

You may be advised to pause tirzepatide before surgery or procedures under sedation or general anaesthetic, because of the risk associated with slower stomach emptying. Always tell the surgical team. See GLP-1 medication before surgery and anaesthesia.

Cost and access

For private patients, long-term cost is a real consideration, especially since the September 2025 list-price change. NHS access via NICE TA1026 is being phased in over several years; at the time of writing, TA1026 does not apply the two-year treatment limit that NICE set for Wegovy under TA875, but local NHS arrangements should be checked. See Mounjaro on the NHS, our Mounjaro prices page and the long-term cost of GLP-1 treatment.

Health monitoring during long-term treatment

Long-term treatment is not just about weight. Depending on your health, your prescriber or GP may suggest periodic checks such as:

• blood pressure, as this often falls with weight loss and some blood pressure medicines may need adjusting
• blood sugar (HbA1c), particularly if you had prediabetes or have type 2 diabetes
• kidney function, especially if you have had episodes of dehydration
• cholesterol and other blood fats
• a review of nutrition, including signs of low intake of protein, iron or vitamins

People with type 2 diabetes should also continue regular eye screening. These checks help confirm that treatment is still benefiting your overall health.

Questions to ask your prescriber about maintenance

• Based on my progress, which maintenance option do you think suits me?
• If I step down, what weight change would prompt us to review again?
• If I stop, what support is available, and how quickly could I restart if needed?
• Do any of my other medicines need changing as my weight stabilises?
• How often will we review my treatment in the long term?

Choosing a provider for long-term care

If you are being treated privately, ongoing support becomes more important during maintenance. Useful questions include whether the provider offers structured maintenance reviews, how they handle step-down requests and how easily you can pause or restart. Our providers page compares regulated services on these features, and our compare pages set providers side by side.

When to speak to a professional

Speak to your prescriber, GP or pharmacist:

• before stopping Mounjaro, reducing your dose or changing how often you inject
• if your weight rises steadily over several weeks after stopping or stepping down
• if you have type 2 diabetes and are planning to stop, as your blood sugar treatment may need changing
• if you are planning a pregnancy, or think you might be pregnant
• if you are due to have surgery or a procedure under sedation or anaesthetic
• if you notice changes in mood or eating behaviour, such as feeling out of control around food

Seek urgent medical help (NHS 111, or 999 in an emergency) if, while taking Mounjaro, you have:

• severe, persistent abdominal pain, which may spread to your back, with or without vomiting
• pain in the upper right abdomen with fever or yellowing of the skin or eyes
• signs of severe dehydration, such as very little urine, dizziness or confusion